Inactive Instrument

Press Releases Auris Medical Holding Ltd Nasdaq

Equities

BMG070251027

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal	Apr. 24	AQ
Altamira Therapeutics : Notice of the Annual General Meeting of Shareholders of Altamira Therapeutics Ltd. (the “Company”) to be held on May 16, 2024 - Form 6-K	Apr. 16	PU
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results	Apr. 10	AQ
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024	Apr. 04	AQ
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines	Mar. 25	AQ
Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal	Feb. 07	AQ
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment	Jan. 24	AQ
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit	Jan. 08	AQ
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement	Dec. 29	AQ
Altamira Therapeutics : Corporate Presentation Winter 2023	Dec. 20	PU
Altamira Therapeutics : Reverse Share Split - Form 6-K	Dec. 11	PU
Altamira Therapeutics Provides Investor and Business Update	Dec. 11	AQ
Altamira Therapeutics : Warrant Inducement Agreement - Form 6-K	Dec. 08	PU
Altamira Therapeutics to Host Investor & Business Update Call on December 11th	Dec. 05	AQ
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement	Nov. 29	AQ
Altamira Therapeutics : Compliance with Continued Listing Rule - Form 6-K	Nov. 22	PU
Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business	Nov. 17	AQ
Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine	Nov. 10	AQ
Altamira Therapeutics : Notice of the Special General Meeting of Shareholders of Altamira Therapeutics Ltd. (the “Company”) to be held on October 31, 2023 - Form 6-K	23-10-04	PU
Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis	23-09-14	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Auris Medical Holding Ltd Nasdaq

Equities

BMG070251027

Press Releases

Filters